AI Article Synopsis
- In pregnancies complicated by hyperthyroidism, treatment with propylthiouracil (PTU) or methimazole (MMI) is necessary to maintain normal thyroid function.
- Both medications are effective but can pose risks of fetal and neonatal hypothyroidism due to their ability to cross the placenta, with MMI potentially linked to specific birth defects.
- The report suggests using PTU as the preferred option and limiting MMI to cases where PTU cannot be used due to allergies or ineffectiveness.
Article Abstract
Background: In hyperthyroidism-complicated pregnancies, medical therapy is necessary to reach an euthyroid condition, and propylthiouracil (PTU) or methimazole (MMI) are used. These drugs are equally effective, but may cause fetal and neonatal hypothyroidism because they freely cross the placenta. Although PTU has not been significantly associated with embryo-fetal anomalies, it has been suggested that MMI might be responsible for a specific embryopathy.
Case(s): Two cases of major congenital anomalies after MMI exposure during pregnancy are reported.
Conclusions: PTU should be the drug of choice, and the use of MMI should be restricted to cases with allergic reactions, intolerance, or poor response to PTU.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/bdra.10098 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!